tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

APRE Stock Latest News

Aprea Highlights Early APR-1051 Data and Financial Update
Company AnnouncementsAprea Highlights Early APR-1051 Data and Financial Update
3d ago
8K
APRE
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
PremiumThe Fly
Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year
3d ago
APRE
Aprea Therapeutics sees cash runway into 1Q27
PremiumThe Fly
Aprea Therapeutics sees cash runway into 1Q27
3d ago
APRE
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
PremiumThe Fly
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
27d ago
APRE
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
PremiumRatings
Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
28d ago
APRE
Aprea Highlights Encouraging Phase 1 Data for APR-1051
PremiumCompany AnnouncementsAprea Highlights Encouraging Phase 1 Data for APR-1051
29d ago
8K
APRE
Aprea Therapeutics announces additional clinical activity for APR-1051
Premium
The Fly
Aprea Therapeutics announces additional clinical activity for APR-1051
29d ago
APRE
Aprea announces expansions of its global intellectual property estate
Premium
The Fly
Aprea announces expansions of its global intellectual property estate
1M ago
APRE
APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
PremiumRatings
APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
1M ago
APRE
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
PremiumThe Fly
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
1M ago
APRE
Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
PremiumThe Fly
Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
1M ago
APRE
Aprea Therapeutics Announces Financing and Early Trial Response
PremiumCompany Announcements
Aprea Therapeutics Announces Financing and Early Trial Response
2M ago
8K
APRE
Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
PremiumThe FlyAprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
2M ago
APRE
Aprea Therapeutics prices 6.29M shares at 89c in private placement
Premium
The Fly
Aprea Therapeutics prices 6.29M shares at 89c in private placement
2M ago
APRE
Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
Premium
The Fly
Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
2M ago
APRE
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
PremiumCompany Announcements
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
2M ago
8K
APRE
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
PremiumThe Fly
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
3M ago
APRE
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
PremiumRatings
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
3M ago
APRE
Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright
PremiumThe Fly
Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright
3M ago
APRE
Aprea Therapeutics CEO issues letter to shareholders
PremiumThe FlyAprea Therapeutics CEO issues letter to shareholders
3M ago
APRE
Aprea Therapeutics Secures $3.1M in Private Placement
Premium
Company Announcements
Aprea Therapeutics Secures $3.1M in Private Placement
3M ago
8K
APRE
Aprea Therapeutics prices 2.62M shares at $1.165 in private placement
Premium
The Fly
Aprea Therapeutics prices 2.62M shares at $1.165 in private placement
3M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >